Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £56.68m
KMK Live PriceLast checked at - London Stock Exchange

Intraday Kromek Share Chart

New Nuclear Security Orders

28 May 2025 07:00

RNS Number : 3101K
Kromek Group PLC
28 May 2025
 

28 May 2025

 

Kromek Group plc 

("Kromek" or the "Group") 

 

New Nuclear Security Orders

Two orders to supply D3 series detectors to a European and a US customer

 

Kromek Group plc (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, is pleased to announce that it has received two orders to supply its D3 series of detectors for use by a European and a US customer.

 

The orders, valued together at approximately $900k, are for immediate delivery. The European customer is dedicated to fostering civilian science and technology partnerships aimed at mitigating global CBRN security risks and advancing non-proliferation efforts. The US customer is a leading supplier of integrated products working in the defence and security sector with a history of implementing innovative security solutions. 

 

The customers will receive the Group's D3 series of detectors to enhance their capabilities in the timely detection of radiation levels, as well as to facilitate data collection and processing and real-time data transmission. This will enable better informed decision-making and rapid responses to potential threats to national safety and security.

 

Arnab Basu, Chief Executive Officer of Kromek, said: "We are pleased to announce the receipt of these new orders that underscore our continued commitment to providing advanced detection solutions for emergency response services. Our proprietary technology is instrumental in mitigating radiological and nuclear threats through rapid, reliable detection and real-time data transmission capabilities.

 

"In an environment marked by ongoing geopolitical uncertainty, demand for our solutions continues to grow, highlighting Kromek's vital role in supporting global safety and security efforts. These orders reflect the increasing trust in our innovative technologies and further solidify Kromek's position as a leading provider in the critical security market."

 

For further information, please contact: 

 

Kromek Group plc 

Arnab Basu, CEO 

Paul Farquhar, CFO 

+44 (0)1740 626 060 

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance 

Tim Redfern - ECM

Michael Johnson - Sales

+44 (0)20 7220 0500 

 

Gracechurch Group (Financial PR) 

Harry Chathli/Claire Norbury/Henry Gamble 

+44 (0)20 4582 3500 

 

Kromek Group plc 

 

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

 

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

 

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.

 

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFFFVIEVIDFIE
Date   Source Headline
4th Apr 20227:00 amRNSNew £1.7m CBRN contract
18th Jan 20227:00 amRNSInterim Results
17th Dec 20214:41 pmRNSSecond Price Monitoring Extn
17th Dec 20214:35 pmRNSPrice Monitoring Extension
14th Dec 20217:00 amRNSNotice of Results
26th Oct 20217:00 amRNSKromek awarded contract by US based OEM customer
29th Sep 20213:14 pmRNSHolding(s) in Company
27th Sep 20211:47 pmRNSDirector Share Purchase
23rd Sep 20217:00 amRNSNuclear security contract from US federal entity
8th Sep 202111:09 amRNSResult of AGM
13th Aug 20213:48 pmRNSNotice of AGM and Publication of Annual Report
3rd Aug 202112:25 pmRNSHolding(s) in Company
15th Jul 202111:05 amRNSSecond Price Monitoring Extn
15th Jul 202111:00 amRNSPrice Monitoring Extension
14th Jul 20217:00 amRNSFinal Results
14th Jul 20217:00 amRNSNew Contracts
1st Jul 20217:00 amRNSNotice of Results
24th Jun 20214:41 pmRNSSecond Price Monitoring Extn
24th Jun 20214:36 pmRNSPrice Monitoring Extension
14th Jun 20217:00 amRNSKromek awarded new DARPA bio-threat contract
12th May 20212:50 pmRNSDirector Share Purchase
11th May 20217:00 amRNSBusiness and Trading Update
21st Apr 20214:32 pmRNSHolding(s) in Company
9th Mar 20217:00 amRNSKromek awarded Nuclear Detection contract
4th Mar 20211:32 pmRNSHolding(s) in Company
2nd Mar 20218:30 amRNSPDMR Dealings
1st Mar 20212:53 pmRNSResults of Placing, Open Offer and General Meeting
1st Mar 20217:00 amRNSNew Medical Screening and Nuclear Security orders
19th Feb 20212:05 pmRNSSecond Price Monitoring Extn
19th Feb 20212:01 pmRNSPrice Monitoring Extension
15th Feb 20217:00 amRNSPosting of Circular
12th Feb 202111:05 amRNSSecond Price Monitoring Extn
12th Feb 202111:00 amRNSPrice Monitoring Extension
12th Feb 202110:30 amRNSPlacing and Open Offer to raise up to £13 million
4th Feb 20212:00 pmRNSIssue of Equity and Total Voting Rights
26th Jan 20215:15 pmRNSHolding(s) in Company
22nd Jan 20214:41 pmRNSSecond Price Monitoring Extn
22nd Jan 20214:35 pmRNSPrice Monitoring Extension
22nd Jan 20212:05 pmRNSSecond Price Monitoring Extn
22nd Jan 20212:00 pmRNSPrice Monitoring Extension
14th Jan 20214:41 pmRNSSecond Price Monitoring Extn
14th Jan 20214:35 pmRNSPrice Monitoring Extension
14th Jan 20219:35 amRNSHolding(s) in Company
13th Jan 20217:01 amRNSFunding to advance Bio-Threat Detection solution
13th Jan 20217:00 amRNSInterim Results
7th Jan 202111:05 amRNSSecond Price Monitoring Extn
7th Jan 202111:01 amRNSPrice Monitoring Extension
16th Dec 20207:00 amRNSDirectorate Changes
14th Dec 202012:45 pmRNSHolding(s) in Company
8th Dec 20207:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.